Cargando…
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report
RATIONALE: Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph+ MPAL) is a rare type of leukemia with poor prognosis. Tyrosine kinase inhibitors (TKIs) in combination with chemotherapy have significantly improved its remission rate. However, relapse remains the major obstacle to achi...
Autores principales: | Lai, Binbin, Mu, Qitian, Zhu, Huiling, Wang, Yi, Zhang, Yi, Xu, Kaihong, Sheng, Lixia, Ouyang, Guifang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902271/ https://www.ncbi.nlm.nih.gov/pubmed/29620650 http://dx.doi.org/10.1097/MD.0000000000010294 |
Ejemplares similares
-
Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
por: Kong, Yuan, et al.
Publicado: (2017) -
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016) -
Cutaneous plaque in adult T cell leukemia/lymphoma: A case report
por: Lei, Chen Shuang, et al.
Publicado: (2020) -
Onset of HLA-B27-associated diseases in diabetic patient during a period of religious fasting: A case report
por: Lin, Zhenyun, et al.
Publicado: (2018) -
Increased circulating Th22 cells in patients with acute gouty arthritis: A CONSORT-compliant article
por: Luo, Guangcheng, et al.
Publicado: (2017)